ERBB2 and breast cancer: While several mechanisms of resistance to trastuzumab or T-DM1 have been described, there is no comprehensive analysis identifying the mechanisms of resistance to T-DXd in HER2+ BC, but it is expected that some mechanisms described for trastuzumab and/or T-DM1 can be extrapolated to T-DXd.